Author

Beatriz Mateos

IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52
IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52

Beatriz Mateos  et al.

CELLULAR IMMUNE RESPONSE TRIGGERED BY GRANULOCYTOAPHERESIS IN ULCERATIVE COLITIS PATIENTS UNDER BIOLOGICAL TREATMENT
CELLULAR IMMUNE RESPONSE TRIGGERED BY GRANULOCYTOAPHERESIS IN ULCERATIVE COLITIS PATIENTS UNDER BIOLOGICAL TREATMENT

Beatriz Mateos  et al.

THE RISKS OF FIRST HEPATIC DECOMPENSATION AND HCC REMAIN CONSTANT DURING LONG-TERM FOLLOW-UP AND CAN BE STRATIFIED BY A ONE-TIME ASSESSMENT AFTER HCV-CURE
THE RISKS OF FIRST HEPATIC DECOMPENSATION AND HCC REMAIN CONSTANT DURING LONG-TERM FOLLOW-UP AND CAN BE STRATIFIED BY A ONE-TIME ASSESSMENT AFTER HCV-CURE

Beatriz Mateos  et al.

VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE
VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE

Beatriz Mateos  et al.

PROGNOSTIC UTILITY OF THE BAVENO VII CRITERIA FOR A CLINICALLY SIGNIFICANT DECREASE IN LIVER STIFFNESS MEASUREMENT AFTER HCV-CURE
PROGNOSTIC UTILITY OF THE BAVENO VII CRITERIA FOR A CLINICALLY SIGNIFICANT DECREASE IN LIVER STIFFNESS MEASUREMENT AFTER HCV-CURE

Beatriz Mateos  et al.

Item 1 - 5 / 5
1